XML 70 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
4. Intangible Assets, Goodwill and Other
 12 Months Ended
Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure
4.    GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):
 
 
2013
 
 
2012
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
$
193.6

 
$
330.0

 
$
523.6

 
 
$
176.8

 
$
319.3

 
$
496.1

Accumulated impairment losses and write-offs
 
(27.2
)
 
(1.0
)
 
(28.2
)
 
 
(27.2
)
 
—

 
(27.2
)
Goodwill, net
 
166.4

 
329.0

 
495.4

 
 
149.6

 
319.3

 
468.9

Acquisitions
 
14.9

 
—

 
14.9

 
 
17.4

 
4.1

 
21.5

Purchase adjustment
 
—

 
—

 
—

 
 
(0.6
)
 
—

 
(0.6
)
Goodwill written off related to excess property
 
—

 
—

 
—

 
 
—

 
(1.0
)
 
(1.0
)
Currency fluctuations
 
0.5

 
7.0

 
7.5

 
 
—

 
6.6

 
6.6

Balances as of December 31:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
209.0

 
337.0

 
546.0

 
 
193.6

 
330.0

 
523.6

Accumulated impairment losses and write-offs
 
(27.2
)
 
(1.0
)
 
(28.2
)
 
 
(27.2
)
 
(1.0
)
 
(28.2
)
Goodwill, net
 
$
181.8

 
$
336.0

 
$
517.8

 
 
$
166.4

 
$
329.0

 
$
495.4



In conjunction with the acquisition of 100% of the outstanding shares of AbD Serotec in our Life Science segment in January 2013, we recorded $14.9 million of goodwill and $44.0 million of definite-lived intangible assets: $33.0 million of developed product technology, $8.8 million of licenses, $1.3 million of customer relationships/lists, $0.4 million of tradenames and $0.5 million of other purchased intangibles. The weighted average useful lives of the definite-lived intangible assets as of the acquisition date were 13.9, 13, 12, 2 and 1 years, respectively, with a total weighted average useful life of 13.7 years.

In December 2012, we sold a building for $6.4 million in our Clinical Diagnostics segment that was associated with a 1999 acquisition. We recognized a gain on the sale of $4.3 million and a portion of the goodwill recorded in a 1999 acquisition was written off of $1.0 million.

In conjunction with the purchase of certain assets from Propel Labs, Inc. in our Life Science segment in August 2012, we recorded $17.4 million of goodwill and $32.1 million of definite-lived intangible assets: $27.3 million of developed product technology, $4.7 million of covenants not to compete and $0.1 million of other intangible assets.

In conjunction with the acquisition of 100% of the outstanding shares of DiaMed Benelux in our Clinical Diagnostics segment in July 2012, we recorded $3.0 million of goodwill and $4.9 million of definite-lived intangible assets: $3.8 million of customer relationships/lists and $1.1 million of tradenames.

In conjunction with the acquisition of certain assets from a raw material supplier in our Clinical Diagnostics segment in January 2012, we recorded $1.1 million of goodwill and $5.1 million of definite-lived intangible assets considered developed product technology.

Other than goodwill, we have no intangible assets with indefinite lives.  Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):
 
December 31, 2013
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-11
 
$
99.8

 
$
(41.1
)
 
$
58.7

Know how
2-12
 
194.6

 
(89.3
)
 
105.3

Developed product technology
1-13
 
109.5

 
(36.2
)
 
73.3

Licenses
1-12
 
44.9

 
(22.4
)
 
22.5

Tradenames
1-9
 
4.3

 
(2.1
)
 
2.2

Covenants not to compete
5-9
 
4.9

 
(0.7
)
 
4.2

Other
—
 
0.6

 
(0.6
)
 
—

 
 
 
$
458.6

 
$
(192.4
)
 
$
266.2


 
December 31, 2012
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-12
 
$
102.8

 
$
(38.4
)
 
$
64.4

Know how
1-13
 
189.3

 
(67.1
)
 
122.2

Developed product technology
1-10
 
74.6

 
(25.1
)
 
49.5

Licenses
1-8
 
35.6

 
(18.7
)
 
16.9

Tradenames
1-10
 
7.4

 
(4.3
)
 
3.1

Covenants not to compete
1-10
 
4.9

 
(0.2
)
 
4.7

Other
1
 
0.1

 
—

 
0.1

 
 
 
$
414.7

 
$
(153.8
)
 
$
260.9



No material impairment losses related to intangible assets were recorded in 2013 or 2012.

Amortization expense related to purchased intangible assets for the years ended December 31, 2013, 2012 and 2011 was $45.0 million, $42.8 million and $39.1 million, respectively.  Estimated future amortization expense (based on existing intangible assets) for the years ending December 31, 2014, 2015, 2016, 2017, 2018 and thereafter is $42.0 million, $39.0 million, $35.6 million, $27.0 million, $24.1 million, and $98.5 million, respectively.